<DOC>
	<DOCNO>NCT02891980</DOCNO>
	<brief_summary>This Phase 1 , double-blind , randomize trial evaluate safety immunogenicity two heterologous two homologous prime-boost regimen use MVA-BN®-Filo Ad26.ZEBOV administer different sequence Days 1 29 healthy adult subject age 18 - 45 years.The study evaluate 'omics ( transcriptomics , proteomics , lipidomics , metabolomics ) , antibodies immunogenicity , CMI , ADCC , lymphoproliferative plasmablast response MVA-BN®-Filo Ad26.ZEBOV vaccine . The primary objective study : 1 ) To Assess safety reactogenicity study group . 2 ) To assess response study vaccination study group first , second third dose transcriptomics . 3 ) To assess peak antibody response study vaccination study group filovirus antigen .</brief_summary>
	<brief_title>MVA-BN®-Filo Ad26.ZEBOV Vaccines Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1 , double-blind , randomize trial evaluate safety immunogenicity two heterologous two homologous prime-boost regimen use MVA-BN®-Filo Ad26.ZEBOV administer different sequence Days 1 29 healthy adult subject age 18 - 45 year . The two heterologous prime-boost group also receive MVA-BN®-Filo day 366 . Sixty subject randomize 1:1:1:1 one four study group ( 15 per group ) .Subjects study staff blind subject 's study vaccine assignment within study vaccination schedule ( e.g. , enrollment Group 1 4 versus 2 3 know ) . The study evaluate 'omics ( transcriptomics , proteomics , lipidomics , metabolomics ) , antibodies immunogenicity , CMI , ADCC , lymphoproliferative plasmablast response MVA-BN®-Filo Ad26.ZEBOV vaccine . The primary objective study : 1 ) To Assess safety reactogenicity study group . 2 ) To assess response study vaccination study group first , second third dose transcriptomics . 3 ) To assess peak antibody response study vaccination study group filovirus antigens . Secondary objective : 1 ) To assess antigen-specific cell-mediated immune ( CMI ) responses study vaccination study group.2 ) To Assess antibody-dependent cell-mediated cytotoxicity ( ADCC ) responses study vaccination study group .</detailed_description>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Marburg Virus Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject must able read provide consent completing informed consent process . Subject must able understand comply plan procedure . Subject must man woman age &gt; /=18 &lt; /=45 year . Subject must body mass index ( BMI ) &gt; /= 18.5 &lt; 35 kg/m2 . Subject must healthy basis patientreported medical history , physical examination , investigator 's clinical judgment . Subject must acceptable laboratory parameters* within 28 day enrollment . Women childbearing potential must negative serum pregnancy test screen negative urine pregnancy test immediately prior study vaccine administration . Women childbearing potential must acceptable method contraception* 28 day prime vaccination least 3 month last boost vaccination . Female subject agrees donate egg ( ovum , oocytes ) purpose assist reproduction start screen onwards least 3 month last boost vaccination . Male subject vasectomy sexually active woman childbearing potential must agree use acceptable method* birth control least 3 month last boost vaccination . Male subject must also agree donate sperm purpose assist reproduction start screen onwards least 3 month last boost vaccination . Subject must available willing participate duration study visit followup ( 19 month enrollment ) . Subject must provide identification . Subject must mean contact . Subjects must consistent access internet perform electronic data entry . Has vaccinate Ebola vaccine . Has diagnose Ebola disease , expose Ebola include travel West Africa 20142016 . Note : West Africa include limited country Guinea , Liberia , Mali , Sierra Leone . Subjects anticipate travel epidemic Ebola area end study also exclude enrollment study . Known suspect receipt adenovirus serotype 26 ( Ad26 ) base vaccine . Known suspected receipt license investigational small pox ( vaccinia ) base vaccine* Note : Includes MVAbased candidate vaccine ( Imvamune Imvanex ) , Dryvax , Acam2000 . Military history review potential subject receipt vacciniabased vaccine . The presence typical vaccinia scar consider exclusionary . Positive serology human immunodeficiency virus ( HIV ) Positive Hepatitis B surface antigen Positive antibody Hepatitis C virus ( HCV ) Known allergy history anaphylaxis serious adverse reaction vaccine vaccine product . Has acute illness temperature &gt; /= 38.0ºC within 3 day prior Day 1 . Female subject pregnant breastfeeding , plan become pregnant enrolled study within 3 month last boost vaccination . A history bleed clot disorder . Any clinically significant acute chronic medical condition , opinion investigator , would preclude participation . History malignancy squamous cell basal cell skin cancer , unless surgical excision consider achieved cure . Prior organ and/or stem cell transplant . Major surgery ( per investigator 's judgment ) within 4 week prior study entry plan major surgery course study . History myocarditis , pericarditis , cardiomyopathy , transient ischemic attack stroke , myocardial infarction , angina , coronary artery disease , congestive heart failure , arrhythmia . Electrocardiogram ( ECG ) clinically significant finding , feature would interfere assessment myocarditis/pericarditis . History diabetes mellitus type 1 type 2 , include case control diet alone . Thyroidectomy thyroid disease require medication last 12 month . Uncontrolled hypertension , define systolic blood pressure &gt; /= 140 mmHg diastolic blood pressure &gt; /= 90 mmHg . Note : Vital sign must normal protocol toxicity grade scale determine normalvariant investigator . In event abnormal heart rate blood pressure due physiological variation activity , subject may rest 10 minute quiet room , blood pressure and/or heart rate may remeasured . Repeated vital sign may use determine eligibility Received license live vaccine within 30 day prior enrollment study , plan receive license live vaccine within 30 day study vaccine . Received licensed inactivated vaccine within 14 day prior enrollment study , plan receive license inactivated vaccine within 14 day study vaccine . Use experimental therapeutic agent within 3 month start screen . Current plan participation another clinical study study period . Receipt blood product immunoglobulin past 3 month . Donation unit blood within 8 week Day 1 p lan donate blood participation study ( start screen onwards ) . Major psychiatric illness past 12 month opinion investigator would preclude participation . Current past abuse recreational narcotic drug . Current past alcohol use judge investigator potentially interfere subject study adherence . History chronic urticaria ( recurrent hive ) . Chronic recurrent use medication modify host immune response ( e.g. , cancer chemotherapeutic agent , parenteral corticosteroid ) . Subject communicate reliably investigator . Subject , opinion investigator , unlikely adhere requirement study . Any condition , opinion investigator , might interfere assess study objective . Personnel involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 25, 2016</verification_date>
	<keyword>Ad26</keyword>
	<keyword>Ebola</keyword>
	<keyword>immunogenicity response</keyword>
	<keyword>MVA-Multi Filo</keyword>
	<keyword>Omics</keyword>
	<keyword>Zaire</keyword>
</DOC>